Key facts
- Rodman & Renshaw initiated coverage on Neurogene.
- Neurogene received a buy rating from Rodman & Renshaw.
- The rating is based on Neurogene's potential in gene therapy.
Rodman & Renshaw has initiated coverage on Neurogene, assigning the stock a buy rating. The investment firm's decision is based on its assessment of Neurogene's potential within the gene therapy sector. Rodman & Renshaw believes the company's pipeline holds significant promise and anticipates future growth opportunities for Neurogene in this specialized area of biotechnology.